# Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study

> **NCT04400474** · PHASE2 · COMPLETED · sponsor: **Grupo Espanol de Tumores Neuroendocrinos** · enrollment: 93 (actual)

## Conditions studied

- Neuroendocrine Tumor
- Anaplastic Thyroid Cancer
- Adenocarcinoma
- Pheochromocytoma
- Paraganglioma

## Interventions

- **DRUG:** Cabozantinib 40 mg

## Key facts

- **NCT ID:** NCT04400474
- **Lead sponsor:** Grupo Espanol de Tumores Neuroendocrinos
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-07
- **Primary completion:** 2023-11-23
- **Final completion:** 2023-12-15
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2025-06-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04400474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04400474, "Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04400474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*